Daniel Lantsberg1,2,3, Adel Farhi4, Inna Zaslavsky-Paltiel4, Barbara G Silverman5,6, Liat Lerner-Geva5,4, Raoul Orvieto7,5,8. 1. IVF Unit, Obstetric and Gynecology Department, Sheba Medical Center, Tel Hashomer, Israel. danielantsberg@yahoo.com. 2. Lis Maternity and Women's Hospital, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel. danielantsberg@yahoo.com. 3. Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. danielantsberg@yahoo.com. 4. Women and Children's Health Research Unit, Gertner Institute for Epidemiology & Health Policy Research Ltd, Tel Hashomer, Israel. 5. Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. 6. Israel National Cancer Registry, Israel Ministry of Health, Tel Aviv, Israel. 7. IVF Unit, Obstetric and Gynecology Department, Sheba Medical Center, Tel Hashomer, Israel. 8. The Tarnesby-Tarnowski Chair for Family Planning and Fertility Regulation, Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel.
Abstract
OBJECTIVE: To evaluate the delivery rate and to characterize patients following ovarian tissue cryopreservation (OTCP) who did not undergo auto-transplantation. METHODS AND MATERIALS: All consecutive cancer patients admitted to our IVF unit, from January 2004 to December 2015, who underwent OTCP for the purpose of fertility preservation without autotransplantation were analyzed. The cohort included 338 patients and was linked to the National Live Birth registry of the Israel Ministry of Health in order to determine whether the women delivered following the cancer diagnosis. MAIN OUTCOME MEASURES: Delivery rate following OTCP without autotransplantation. RESULTS: During 6.4 years of follow-up, 30% of the patients delivered, with no differences in gravity, age at first diagnosis of cancer, type of malignancy, or the prevalence of relapse of malignancy between those who delivered and those who did not. Moreover, in multivariate analysis, those undergoing OTCP before the age of 30 and those suffering from breast cancer had significantly higher odds to conceive and deliver following cancer treatment without the need of autotransplantation. CONCLUSIONS: Further studies are required to elucidate the appropriate subgroup of patients with breast cancer under the age of 30 years, who will need OTCP. This information might aid both fertility specialists' counseling and their oncological patients in pursuing the appropriate fertility preservation strategy.
OBJECTIVE: To evaluate the delivery rate and to characterize patients following ovarian tissue cryopreservation (OTCP) who did not undergo auto-transplantation. METHODS AND MATERIALS: All consecutive cancerpatients admitted to our IVF unit, from January 2004 to December 2015, who underwent OTCP for the purpose of fertility preservation without autotransplantation were analyzed. The cohort included 338 patients and was linked to the National Live Birth registry of the Israel Ministry of Health in order to determine whether the women delivered following the cancer diagnosis. MAIN OUTCOME MEASURES: Delivery rate following OTCP without autotransplantation. RESULTS: During 6.4 years of follow-up, 30% of the patients delivered, with no differences in gravity, age at first diagnosis of cancer, type of malignancy, or the prevalence of relapse of malignancy between those who delivered and those who did not. Moreover, in multivariate analysis, those undergoing OTCP before the age of 30 and those suffering from breast cancer had significantly higher odds to conceive and deliver following cancer treatment without the need of autotransplantation. CONCLUSIONS: Further studies are required to elucidate the appropriate subgroup of patients with breast cancer under the age of 30 years, who will need OTCP. This information might aid both fertility specialists' counseling and their oncological patients in pursuing the appropriate fertility preservation strategy.
Authors: R Imbert; F Moffa; S Tsepelidis; P Simon; A Delbaere; F Devreker; J Dechene; A Ferster; I Veys; M Fastrez; Y Englert; I Demeestere Journal: Hum Reprod Date: 2014-06-22 Impact factor: 6.918
Authors: Ahmed A Mohamed; Tarek K Al-Hussaini; Mohamed M Fathalla; Tarek T El Shamy; Ibrahim I Abdelaal; Saad A Amer Journal: Am J Obstet Gynecol Date: 2016-04-05 Impact factor: 8.661
Authors: Joseph M Letourneau; Michelle E Melisko; Marcelle I Cedars; Mitchell P Rosen Journal: Nat Rev Clin Oncol Date: 2010-08-24 Impact factor: 66.675
Authors: Stephanie J Lee; Leslie R Schover; Ann H Partridge; Pasquale Patrizio; W Hamish Wallace; Karen Hagerty; Lindsay N Beck; Lawrence V Brennan; Kutluk Oktay Journal: J Clin Oncol Date: 2006-05-01 Impact factor: 44.544
Authors: Alison W Loren; Pamela B Mangu; Lindsay Nohr Beck; Lawrence Brennan; Anthony J Magdalinski; Ann H Partridge; Gwendolyn Quinn; W Hamish Wallace; Kutluk Oktay Journal: J Clin Oncol Date: 2013-05-28 Impact factor: 44.544
Authors: Michael von Wolff; Jacques Donnez; Outi Hovatta; Victoria Keros; Theodoris Maltaris; Markus Montag; Bruno Salle; Murat Sonmezer; Claus Yding Andersen Journal: Eur J Cancer Date: 2009-03-04 Impact factor: 9.162
Authors: Maren Goeckenjan; A Freis; K Glaß; J Schaar; I Trinkaus; S Torka; P Wimberger; A Germeyer Journal: Arch Gynecol Obstet Date: 2020-05-06 Impact factor: 2.344